Patient-reported Outcomes (pros) with Talazoparib (TALA) Plus Enzalutamide (ENZA) Vs. Placebo (PBO) Plus ENZA in Men with Metastatic Castration-Resistant Prostate Cancer (mcrpc): Subgroup Analysis of Patients with Novel Hormonal Therapy (NHT) Pretreatment in the TALAPRO-2 Study.
JOURNAL OF CLINICAL ONCOLOGY(2024)
关键词
261-492-6491,283-2494-5577-2829-12292,261-492-199-2823,60,1866,60
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要